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ABSTRACT
Objective To develop a population screening strategy for
familial hypercholesterolaemia.
DesignMeta-analysis of published data on total and low
density lipoprotein (LDL) cholesterol in people with and
without familial hypercholesterolaemia according to age.
Thirteen studies reporting on 1907 cases and 16221
controls were used in the analysis. Included studies had
at least 10 cases and controls with data on the
distribution of cholesterol in affected and unaffected
individuals.
Main outcome measures Detection rates (sensitivity) for
specified false positive rates (0.1%, 0.5%, and 1%) in
newborns and in age groups 1-9, 10-19, 20-39, 40-59,
and ≥60 years.
Results Serum cholesterol concentration discriminated
best between people with and without familial
hypercholesterolaemia at ages 1-9, when the detection
rates with total cholesterol were 88%, 94%, and 96% for
false positive rates of 0.1%, 0.5%, and 1%. The results
were similar with LDL cholesterol. Screening newborns
was much less effective. Once an affected child is
identified, measurement of cholesterol would detect
about 96% of parents with the disorder, using the simple
rule that the parent with the higher serum cholesterol
concentration is the affected parent.
Conclusions The proposed strategy of screening children
and parents for familial hypercholesterolaemia could
have considerable impact in preventing the medical
consequences of this disorder in two generations
simultaneously.
INTRODUCTION
Familial hypercholesterolaemia is an autosomal domi-
nant disorder affecting about two in every 1000
people.1 It results in increased serum cholesterol con-
centrations and a high mortality from coronary heart
disease. Affected adults aged 20-39 years have a 100-
fold excess risk of dying from coronary heart disease.w1
Treatment to lower serum cholesterol concentration,
for example with statins, is effective in prevention2 so
screening for familial hypercholesterolaemia may be a
practical option if an effective population screening
strategy were available. Cascade screening, in which
the first degree relatives of affected individuals are
tested,3 4 is currently being assessed as part of a
nationwide pilot screening programme. At present,
there is no effective way of identifying index cases in
the population and so there remains uncertainty over
what screening strategy is likely to be effective.
We carried out a meta-analysis of published studies
on total and LDL cholesterol in individuals with and
without familial hypercholesterolaemia to determine
the age at which cholesterol measurement discrimi-
nates best between affected and unaffected, to quantify
the screening performance of suchmeasurements, and
to propose a screening strategy that could be applied to
the whole population in an efficient manner.
METHODS
We sought published studies that included data on the
distributions of serum total or LDLcholesterol concen-
trations in cases of heterozygous familial hypercholes-
terolaemia and unaffected controls. We searched
electronic databases (Medline, Embase, and the
Cochrane Library) in any language up to May 2006,
using key words [hypercholesterolemia or hypercho-
lesterolaemia] and [familial or heterozygous] and
within resulting citations identified studies on humans
and those of Medline subsets “diagnosis,” or “clinical
prediction guides.”We examined relevant citations in
the reports of studies and in review articles. In studies
that reported incomplete data we contacted the indivi-
dual authors for the required information.
We included studies with 10 or more cases that pub-
lished themean and SDs of total or LDL cholesterol (or
data from which they could be derived) for which cor-
responding data in unaffected controls were either
published by the authors or identified separately by
us from population surveys.
The studies were included if the diagnosis of familial
hypercholesterolaemia was genetically or clinically
confirmed. Cases were identified from lipid
clinicsw1-w3 w5-w13 or through screening the general
population.w4 Genetic diagnosis required the identifi-
cation of amutation in the LDL receptor gene byDNA
analysis. Clinical diagnosis required a measurement of
total or LDL cholesterol concentration above a given
level (which varied between studies—for example,
above the 90th or 95th centiles), a raised serum choles-
terol concentration in a first degree relative, and a
family history of tendon xanthomata. Controls were
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from healthy populations stratified by age, geographi-
cal region, and the time period (generally within five
years) when the blood samples in cases were collected.
In seven out of the nine comparisons with genetically
confirmed cases the controls were taken from siblings
in whom DNA analysis identified no disease causing
mutations, but they were not necessarily in the same
age strata as their sibling “case.” We excluded case-
control comparisons in which the cases of familial
hypercholesterolaemia were classified as those with
high cholesterol concentrations (such as ≥90th centile)
and controlswith concentrations less than the 90th cen-
tile, as have been used in previous assessments of
screening,5-7 as this by definition classifies people as
being affected andunaffectedwithout any independent
corroboration. We excluded studies of patients taking
lipid lowering treatment and in which the cases were
drawn from a population where the age range
exceeded 20 years.
We log transformed serum cholesterol concentra-
tions because the distributions of LDL and total cho-
lesterolwere positively skewed.Thiswas confirmedby
results from studies in which the individual data points
for serum cholesterol concentrations were published
and probability plots indicated a good fit to a logGaus-
sian distribution. The mean and SD of the log choles-
terol values that describe the Gaussian distribution for
each study were derived from the reported untrans-
formedmeans andSDs in each study and the published
formula for the mean and SD of the log Gaussian
distribution.8 In one study that provided individual
data on newborns, there was one outlying value (with
very low total and LDL cholesterol levels),w3 which we
excluded from the analysis. Including it had a minor
effect on the results.
Data in the studies were categorised into six age
groups. Within each age group we calculated an over-
all mean (and SD) of the log10 total and LDL choles-
terol concentrations for cases and controls, weighted
by the number of cases and controls respectively, set-
ting the upper limit for controls at 100 to avoid large
control groups dominating the overall average
(weighting by 1/SE2 gave similar results). As choles-
terol values fit a log Gaussian distribution, the mean
of the log transformed values when anti-logged is well
estimated by the untransformed median value. We
therefore used the median as the preferred measure
of central tendency and have expressed the results as
multiples of themedian (MoM) in controls (themedian
MoM in controls is thus 1.0). This approach was ori-
ginally described in screening for neural tube
defects9 10 and is widely used in antenatal screening
for Down’s syndrome.11
We estimated screening performance from the over-
lapping Gaussian distributions of total and LDL cho-
lesterol (expressed as log10 MoM values) within each
age group in cases and controls. The false positive rate
(the proportion of unaffected individuals with positive
Table 1 | Source and number of cases of familial hypercholesterolaemia and controls according to age (numbers in parentheses
are numbers of LDL cholesterolmeasurements if they differed fromnumbers of total cholesterolmeasurements)
Age group (years) and study
Number of
Country Diagnosis of cases Description of controlsCases Controls
Newborn
Vuoriow2 13* 10* Finland DNA analysis Siblings without mutations
Kwiterovitchw3 16 (12) 36 USA Clinical Unrelated healthy newborns
1-9
Vuoriow2 18 16 Finland DNA analysis Siblings without mutations
Ohtaw4 91 65 Japan Clinical Unrelated healthy children
Vuoriow5 47 40 Finland DNA analysis Siblings without mutations
Westw6 35 (0) 13 923 (0) USA Clinical Unrelated healthy children†
Assoulinew7 62 41 Canada DNA analysis Unrelated healthy children
10-19
Wiegmanw8 742 189 Holland DNA analysis Siblings without mutations
Vuoriow5 44 31 Finland DNA analysis Siblings without mutations
Kwiterovitchw9 105 (0) 81 (0) USA Clinical Unrelated healthy children
Ketomakiw10 18 29 Finland DNA analysis Siblings without mutations
Tonstadw11 63 (0) 30 (0) Norway DNA analysis Unrelated healthy children
20-39
Vuoriow5 127 (126) 40 Finland DNA analysis Siblings without mutations
Simon Broome registerw1 214 804 (799) England Clinical Unrelated healthy adults‡
40-59
Simon Broome registerw1 237 721 (720) England Clinical Unrelated healthy adults‡
≥60
Simon Broome registerw1 75 165 England Clinical Unrelated healthy adults‡
*Not including one outlying observation.
†Lipid research clinics 1979.w12
‡Diet and nutrition survey 1986.w13
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results) was set at about 1% or less, as would be accep-
table for population screening.We estimated detection
rates (the proportion of affected individuals with posi-
tive results) using cholesterol cut offs (expressed as
MoM values) to define false positive rates of 0.1%,
0.5%, and 1%. The 95% confidence intervals on the
detection rates were based on binomial probabilities.
Within each age group we assessed heterogeneity by
one way analysis of variance (ANOVA) of mean log10
MoM values in cases and controls.
RESULTS
Table 1 lists the 13 studies included in the analysis
according to country of origin and method used to
diagnose familial hypercholesterolaemia, categorised
into six age groups. The studies included a total of
1907 individuals with familial hypercholesterolaemia
(1134 with a DNA confirmed diagnosis and 773 a clin-
ical diagnosis) and 16 221 controls.w1-w13 The reported
means and SDs for total and LDL cholesterol in the
individual studies and the same data expressed as
log10 mmol/l and the combined weighted mean log10
serum cholesterol concentrations for cases and con-
trols in each age group can be found on our website
(www.wolfson.qmul.ac.uk/epm/webtables/).
Table 2 shows the weighted average median MoM
value of total and LDL cholesterol concentrations in
cases and controls for each age group (with log10 SD).
Table 2 | Pooledmedian,median log10, andmultiples of themedian (MoM) serum total and LDL cholesterol concentrations in cases and controls according to age
Age group
(years)
Concentration (mmol/l) Concentration (MoM)
Cases Controls Cases Controls
Median Median (SD) (log
10)*
Median Median (SD) (log
10)*
Median Median (SD) (log
10)
Median
Median (SD)
(log
10)
Total cholesterol
Newborn 2.59 0.4139 (0.0829) 1.81 0.2567 (0.0639) 1.44 0.1572 (0.0829) 1.0 0 (0.0639)
1-9 7.80 0.8922 (0.0752) 4.16 0.6195 (0.0594) 1.87 0.2727 (0.0752) 1.0 0 (0.0594)
10-19 7.27 0.8614 (0.0940) 4.31 0.6347 (0.0711) 1.69 0.2267 (0.0940) 1.0 0 (0.0711)
20-39 8.79 0.9439 (0.1019) 5.12 0.7091 (0.0775) 1.72 0.2348 (0.1019) 1.0 0 (0.0775)
40-59 8.68 0.9383 (0.1162) 6.14 0.788 (0.0810) 1.41 0.1503 (0.1162) 1.0 0 (0.0810)
≥60 8.42 0.9252 (0.1183) 6.62 0.821 (0.0740) 1.27 0.1042 (0.1183) 1.0 0 (0.0740)
LDL cholesterol
Newborn 1.67 0.2230 (0.1181) 0.78 -0.1065 (0.0844) 2.14 0.3295 (0.1181) 1.0 0 (0.0844)
1-9 5.95 0.7744 (0.0954) 2.59 0.4126 (0.0854) 2.30 0.3618 (0.0954) 1.0 0 (0.0854)
10-19 5.45 0.7364 (0.1220) 2.42 0.3843 (0.1125) 2.25 0.3521 (0.1220) 1.0 0 (0.1125)
20-39 7.09 0.8506 (0.1212) 3.62 0.5586 (0.1117) 1.96 0.2920 (0.1212) 1.0 0 (0.1117)
40-59 6.74 0.8285 (0.1533) 4.82 0.6830 (0.1070) 1.40 0.1455 (0.1533) 1.0 0 (0.0170)
≥60 6.01 0.7791 (0.1484) 5.28 0.7230 (0.0990) 1.14 0.0561 (0.1484) 1.0 0 (0.0990)
*Median log10 cholesterol concentration is directly estimated from mean log10 cholesterol concentration (see www.wolfson.qmul.ac.uk/epm/webtables/), which anti-logged gives median
values shown in this table.
Table 3 | Detection rates (with 95%confidence intervals) for familial hypercholesterolaemia based on total and LDL cholesterol
measurements according to specified false positive rates, age, and cholesterol cut-off levels (expressed inmultiples of the
median in controls (MoM))
Age group
(years) Studies
False positive rate (%)
0.1% 0.5% 1%
Detection rate (95% CI)
Cut off
(MoM) Detection rate (95% CI)
Cut off
(MoM) Detection rate (95% CI) Cutoff (MoM)
Total cholesterol
Newborn 2 31 (15 to 51) 1.58 46 (26 to 64) 1.46 54 (36 to 74) 1.14
1-9 5 88 (84 to 92) 1.53 94 (91 to 97) 1.42 96 (93 to 98) 1.37
10-19 5 53 (50 to 56) 1.66 68 (65 to 71) 1.52 74 (71 to 77) 1.46
20-39 2 48 (43 to 54) 1.74 64 (58 to 69) 1.58 70 (65 to 75) 1.51
40-59 1 19 (15 to 25) 1.78 31 (25 to 37) 1.62 37 (31 to 44) 1.54
≥60 1 15 (8 to 25) 1.69 23 (14 to 34) 1.55 28 (18 to 40) 1.49
LDL cholesterol
Newborn 2 72 (51 to 88) 1.82 83 (64 to 95) 1.65 87 (69 to 97) 1.57
1-9 4 85 (79 to 89) 1.84 93 (89 to 96) 1.66 96 (92 to 98) 1.58
10-19 3 51 (48 to 55) 2.23 70 (66 to 73) 1.95 77 (74 to 80) 1.83
20-39 2 33 (29 to 38) 2.21 51 (46 to 57) 1.94 60 (55 to 66) 1.82
40-59 1 11 (8 to 16) 2.14 20 (15 to 25) 1.89 25 (20 to 31) 1.77
≥60 1 5 (1 to 11) 2.02 9 (3.8 to 18) 1.80 12 (6 to 22) 1.70
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The medianMoM in cases was greatest in the 1-9 year
old age group (1.87 for total cholesterol and 2.30 for
LDL cholesterol) and the SDs tended to be the lowest
in this age group, indicating that the greatest discrimi-
nation between affected and unaffected individuals
occurred at age 1-9 years.
Table 3 shows the detection rates (separately for total
and LDL cholesterol) in the six age groups, according
to specified false positive rates (0.1%, 0.5%, and 1.0%),
together with the corresponding cholesterol cut-off
levels (in MoM values) that determine these false posi-
tive rates. At a given false positive rate the detection
rate was greatest at 1-9 years and declined with
increasing age. At a false positive rate of 0.1%, for
example, the detection rate in the 1-9 year age group,
based on total cholesterol measurement, was 88% (or
85% with LDL cholesterol) but only 31% (or 72% with
LDL cholesterol) in newborns and as low as 5% at 60
and over.Within the 1-9 year age group, the screening
performance seemed to peak at between 1 and 2 years
of age, based on two studiesw4 w5 that together yielded
detection rates of 92% (with total cholesterol) or 89%
(with LDL cholesterol) for a 0.1% false positive rate.
Figure 1 shows the detection rate plotted against the
false positive rate for total and LDL cholesterol mea-
sured at different ages. This illustrates the maximum
discrimination at 1-9 years and shows that there is little
additional increase in the detection rate as the false
positive rate increases above 1%.
Sensitivity analyses showed that the estimates are
robust because we obtained similar results for males
and females separately, genetically confirmed cases
and clinically diagnosed cases separately, cases taken
from lipid clinics or identified through mass screening
separately, and studies that used unrelated controls or
sibling controls separately. For example, for total cho-
lesterol in the 1-9 age group, the estimate of screening
performance at a 0.5% false positive was a 94% detec-
tion rate with studies that used unrelated controls com-
pared with a 96% detection rate with studies that used
sibling controls. There was no evidence of heterogene-
ity in the detection rates across the studies in children
aged 1-9 years (fig 2), despite there being heterogeneity
between mean cholesterol concentrations in cases or
controls (P≤0.02) as would be expected from dietary
variations between populations in different parts of
the world, measured at different points in time.
DISCUSSION
Measurement of serum cholesterol concentration dis-
criminates best between individuals with and without
familial hypercholesterolaemia in children aged
1-9 years, when a high detection rate can be achieved
for a false positive rate of 0.1%. Screening performance
is materially reduced in newborns and young adults.
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Fig 1 | Plots of detection rates against false positive rates for
total and LDL cholesterol concentrations according to age in
years
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Fig 2 | Estimated detection rate for a 0.1% false positive rate for total and LDL cholesterol according to studies in children aged
1-9 years
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The results indicate that population screening could be
highly effective.
Figure 3 shows, for both total and LDL cholesterol,
the distributions in affected and unaffected individuals
aged 1-9 years.Cholesterol cut offs that yield false posi-
tive rates of 0.1%, 0.5%, and 1% are shown with the
corresponding detection rates and the corresponding
likelihood ratios for individuals at or above the speci-
fied cut offs. The figure shows how small differences in
the selected cut off for serum cholesterol concentration
have relatively large effects on the false positive rate
but smaller effects on the detection rate. The likelihood
ratio (the detection rate divided by the false positive
rate) indicates the number of times people who are
screen positive are at an increased risk of being affected
compared with people in general. So, for example,
with a total cholesterol cut off of 1.53 MoM, on aver-
age, individuals with a positive result on screening
have 880 times the chance of being affected than peo-
ple in general.With a cut off only slightly lower, at 1.37
MoM, the likelihood ratio drops to 96. In viewof this, if
screeningwere introduced it would be sensible to do so
using a cholesterol cut off of about 1.53 MoM rather
than 1.37 as the detection rate is only 8 percentage
points lower and the likelihood ratio is about nine
times greater.
There was no advantage in measuring LDL choles-
terol over total cholesterol, apart from in screening
newborns (when LDL cholesterol was better), but this
is too early for screening. In general, the measurement
of total cholesterol was marginally (but not signifi-
cantly) better than LDL cholesterol measurement as a
screening test. This might reflect a coincident rise in
other lipoprotein concentrations (very low density
lipoprotein and intermediate density lipoprotein) in
people with familial hypercholesterolaemia.12
The advantage of using MoM values rather than
absolute mass units (such as mmol/l) is that they tend
to overcome systematic variation between laboratories
in serum cholesterol measurement, provide a simple
measure of how high or low a person’s cholesterol is
compared with a typical “average” population level,
and a given MoM cut off will tend to yield the same
screening performance (detection rates and false posi-
tive rates) in different populations. Within a given
population any MoM value can easily be converted
into a local cholesterol concentration cut off in
mmol/l. For example, our results indicate that a
MoM cut off of 1.53 (table 3) will have a detection
rate of 88% and a false positive rate of 0.1% at ages 1-
9. If the median total cholesterol in a given population
of 1-9 year olds was 4 mmol/l the cut off would be
1.53×4 mmol/l or 6.1 mmol/l. In practice it may be
better to convert all serum cholesterol values in to
MoM values by using local normal cholesterol med-
ians, as is routinely done in antenatal screening for
neural tube defects and Down’s syndrome.11
The confidence intervals on our results are narrow.
They reflect sample size but do not take in to account
possible imprecision arising from variation in esti-
mates between studies and deviation of fit of the data
from a Gaussian distribution. The sensitivity analyses,
however, indicate that we can be reasonably confident
in the results, particularly in relation to the relative dif-
ferences between the age groups. Some cases of famil-
ial hypercholesterolaemia may have been missed
because not all mutations are known, but this would
not lead to bias if the cholesterol distributions in people
with known and unknown mutations were similar. If
cholesterol concentrations in people with “unknown”
mutationswere, on average, lower than those in people
with “known” ones, screening performance would be
overestimated, or underestimated if they were higher.
Such “missed” cases are, however, unlikely to repre-
sent an important source of bias because it is estimated
that over 80% of mutations have been identified.13
Proposed population screening strategy
Serum cholesterol measurement in children
Children could be screened when they visit their gen-
eral practice for routine vaccination at about
15 months of age (for example, when attending for
themeasles, mumps, and rubella (MMR) vaccination).
A blood spot could be collected at the same time as the
vaccination is given. Use of an appropriate total (or
LDL) cholesterol cut off that yields a false positive
rate of 0.1% (for example, 1.53 MoM and 1.84 MoM,
Unaffected
Familial hypercholesterolaemia
Total cholesterol (MoM)
Total cholesterol
0.5 1 2
1.53 MoM
DR=88%
880
Likelihood
ratio
FPR=0.1%
3 4 5
1.42 MoM
DR=94%
198
FPR=0.5%
1.37 MoM
DR=96%
96
FPR=1%
LDL cholesterol (MoM)
LDL cholesterol
0.5 1 2
1.84 MoM
DR=85%
850
Likelihood
ratio
FPR=0.1%
3 4 5
1.66 MoM
1.58 MoM
196
96
DR=93%
FPR=0.5%
DR=96%
FPR=1%
Fig 3 | Relative frequency distributions of total and LDL cholesterol in children aged 1-9with and
without familial hypercholesterolaemia, showing detection rates (DR) and likelihood ratios for
cholesterol cut offs set to yield false positive rates (FPR) of 0.1%, 0.5%, and 1%
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respectively, based on the results from this analysis)
would identify about 90% of cases.
Serum cholesterol measurement in parents
As familial hypercholesterolaemia is an autosomal
dominant disorder, a child with the disorder will have
an affected parent. The identification of affected chil-
dren aged 1-9 provides an opportunity to identify
affected parents. Screening children in this way there-
fore accomplishes two aims simultaneously: screening
children and screening their parents. Treatment to
lower cholesterol could be initiated immediately in
the parent and delayed in the child until adulthood.
Measurement of serum cholesterol (total or LDL) in
each parent of an affected child would determine
whichone is affected.Applying a simple rule—namely,
that the parent with the higher cholesterol concentra-
tion has the disorder—is an effective way of determin-
ing which parent is affected, with a detection rate of
about 96%. The accuracy of this rule can be estimated
from the distributions of serum cholesterol concentra-
tion in affected and unaffected individuals aged 20-29
(shown for LDL cholesterol in fig 4). The distribution
of the differences between affected andunaffected indi-
viduals is estimated by subtracting themeans and sum-
ming the variances (expressed in logs as LDL
cholesterol has a log Gaussian distribution) and this
can be expressed as the ratio of LDL cholesterol in
pairs of affected and unaffected people (shown in
fig 4). The shaded area indicates the proportion of dif-
ferences below one (affected less than unaffected) and
represents the proportion of parents who would be
misclassified according to the rule—4% for LDL cho-
lesterol (3% for total cholesterol), leaving 96% (100%
−4%) correctly identified. In this situation a 4% false
negative rate equals the false positive rate because for
every missed affected parent the other unaffected par-
ents will be classified as positive. The cholesterol dis-
tributions in figure 4 are shown inMoMs so the results
are generalisable; in practice, all that need be done is to
identify the parent with the higher serum cholesterol
concentration. In about one in 500 screen positive chil-
dren, both parents will be affected, but this has aminor
effect on the detection rate in parents (reducing it by
only about 0.2%). It has been estimated that the father
is not the biological parent in about 4% of families,14 so
about 2% of men tested in this way would bemisclassi-
fied as having the disorder when they did not. But this
LDL cholesterol ratios
LDL cholesterol (MoM)
0.1 0.50.25 1 2 3 4 5 6 7 8 10
0.25 0.5 1 2 3 4 5 6 8
Unaffected
Familial hypercholesterolaemia (affected)
4%
Fig 4 | Top: distributions of LDL cholesterol (MoMs) in
individuals aged 20-39 with and without familial
hypercholesterolaemia; bottom: distribution of ratio of all
possible pairs of affected and unaffected individuals with
familial hypercholesterolaemia (shaded area (4%) indicates
proportion of differences <1 (affected less than unaffected)
and represents proportion of parents who would be
misclassified if parent with higher cholesterol concentration
was assumed to have disorder)
10 000 children
aged about
15 months
Effect of screening children without DNA diagnosis
20 familial
hypercholesterolaemia
9980
unaffected
18
Total cholesterol
≥1.53 MoM
Total cholesterol
≥1.53 MoM
10
14
Presence of LDL
receptor mutant
0
Positive predictive
value = 18/28
(64%)
Detection
rate (88%)
False positive
rate (0.1%)
Detection
rate (80%)
False positive
rate (0%)
10 000 children
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15 months
20 familial
hypercholesterolaemia
9980
unaffected
18
10
Detection
rate (88%)
False positive
rate (0.1%)
Effect of screening children with DNA diagnosis
Positive predictive
value = 14/14
(100%)
Fig 5 | Effect of screening children without and with DNA diagnosis
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would apply to only about 1 in 25 000men (2%of 2 per
1000).
Expected impact of proposed screening strategy
Figure 5 shows two flowdiagrams to illustrate the effect
of screening a population of 10 000 children attending
for vaccination at 15 months of age, one without and
onewith the use ofDNAdiagnosis.Given a prevalence
of familial hypercholesterolaemia of two per 1000,
there should be 20 affected and 9980 unaffected chil-
dren. Eighteen out of the 20 affected childrenwould be
detected and 10 unaffected children would be falsely
classified as positive (from table 3, detection rate 88%
for a 0.1% false positive rate). The odds of being
affected given a positive result is therefore about 2:1
(18:10); the positive predictive value being 64% (18/
28). There is no diagnostic test available that can iden-
tify all affected individuals so intervention would have
to be based on the screening results alone. Alterna-
tively, DNA analysis to identify LDL receptor muta-
tions could be used in children with positive results
on screening (lower flow diagram in fig 5). This has
the advantage of excluding all false positives (positive
predictive value 100%) but at the expense of missing
20% of affected children because not all mutations
have been identified.13
Figure 6 shows the effect of parental testing without
and with DNA diagnosis. Without DNA diagnosis,
parents of a child with positive results on screening
would be offered measurement of serum cholesterol.
Adoption of the rule that the parent with the higher
cholesterol concentration has the disorder would cor-
rectly identify 17 affected parents (96% of 18) and fal-
sely classify 11 unaffected parents as positive (10 false
positives from the screening of the children and one
from parental screening; see fig 6). Treatment to
lower serum cholesterol would be offered to each par-
ent with positive results on screening (and later to the
child), recognising that out of about every three indivi-
duals identified one would not have the inherited
abnormality.
The alternative strategy usingDNAdiagnosis would
correctly identify all the affected parents of affected
children but would miss the 20% of affected parents
of children who had an undetectable mutation. It
would be necessary to test the parent only for themuta-
tion found in the child. Screening without DNA diag-
nosis has the advantage of being simpler and less
expensive.
A strength of the proposed child-parent strategy is
that the “population sweep” to identify index cases
through screening children would not need to be
repeated indefinitely. Once a “critical mass” of “seed”
families had been identified (which may take about
30 years as most children are born to women aged
15-45), measurement of serum cholesterol concentra-
tion in all first degree relatives could thereafter be used
to identify the remaining people with familial hyperch-
olesterolaemia in the population—so called “cascade
screening.” This concept has been summarised34 and
judged potentially useful for autosomal dominant dis-
orders like familial hypercholesterolaemia but not for
autosomal recessive disorders such as cystic fibrosis.
Our strategy is a screening approach that offers a
simple means of screening children, their parents,
and then their family members for familial
hypercholesterolaemia. The strategy fulfils eight
out of the 10 requirements for a worthwhile screening
programme15; two criteria (availability of facilities for
implementation and cost effectiveness) have yet to be
determined. There are practical challenges in imple-
mentation. A pilot study and a simple means of blood
sampling at the time of vaccination would be needed.
A potential strength of screening at the time of child-
hood immunisation is that it would take place at a time
when parents are receptive to the possibility of
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Fig 6 | Flow diagrams to illustrate the effect of screening parents of affected children without and with DNA diagnosis
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preventing disease in their child and therefore may be
receptive to a family based strategy to prevent the con-
sequences of the same disease within the family as a
whole. Systems would need to be developed to track
affected children over time to ensure that appropriate
treatment is started when they are older. If, after a few
decades, the uptake of screeningwere high enough, the
need to test children at 15 months of age would disap-
pear because all or nearly all affected individuals
would be known and it would be necessary to test
only the children of families known to have the disor-
der. The strategy has the potential to prevent a major
cause of coronary heart disease in young adults.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Familial hypercholesterolaemia is an autosomal dominant disorder affecting about two per
1000 people
The disorder results in a high mortality from coronary heart disease
Lowering serum cholesterol reduces risk substantially, but there is no accepted strategy for
population screening
WHAT THIS STUDY ADDS
Screening by measurement of serum cholesterol is most effective if done in early childhood
after the first year of life; between ages 1 and 9 years, an estimated 88% of affected children
would be identified with a false positive rate of 0.1%
For every affected child there would be one affected parent, identifiable as the one with the
higher serum cholesterol concentration
Such a proposed child-parent screening strategy has the potential to prevent the medical
consequences of this disorder in two generations simultaneously
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